ELV

ACCE-researched
Elevance Health Inc. Common Stock
Healthcare · Healthcare Plans · NYSE · United States
$409.31-0.40%
Market cap $88.8BNext earnings 2026-10-20Updated Sep 20, 2026
FAIR VALUE · CONSENSUS
$409.31+0.0%
confidence-weighted across 5 of 6 models
Now $409.31
$409.31
$340.91$701.23
BuySilver73
Price vs fair value
19.6% below
+24.4% to fair value
ACCE score
58
out of 100
Analysts
82% buy
22 covering
P/E
18.1x
forward 13.9x
1-year return
+30.5%
Dividend yield
1.67%
Unlock the ACCE read
INVESTOR

Overview

⚠ Investor warnings · 3 flags
  • high
    Earnings decline severe
    Earnings YoY down 16.8%, signaling meaningful profitability deterioration despite 2.6% revenue growth.
  • high
    Margin compression evident
    Operating margin only 5.3% and net margin 2.6%, thin for managed care; suggests rising medical costs outpacing premiums.
  • moderate
    Revenue growth decelerating
    Rev YoY +2.6% vs 5-year CAGR +11.3% represents sharp deceleration, raising questions about competitive or enrollment pressures.
Reports in 28 days, last quarter beat by 0.2%.

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Price

+28.8% · 1Y

Valuation

INVESTOR
Full valuation engine INVESTOR FEATURE

Six independent models converge on one confidence-weighted fair value, with full methodology and editable assumptions.

  • +All six models: DCF, P/E and EV/EBITDA comps, Graham, dividend discount, residual income
  • +Scenario bands, sensitivity tornado, and the 5-year historical valuation range
  • +Editable DCF workbench with saved scenarios

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: conviction breakdown, earnings quality, score history, and backtested returns.

  • +Conviction score breakdown and earnings-quality grade
  • +Growth / value / quality / momentum component scores
  • +90-day score history and score-threshold backtests

Analysts

Wall Street consensus

Bullish82% buy · 22 covering analysts
● Strong buy 13● Buy 5● Hold 4● Sell 0● Strong sell 0
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO
Smart money tracking PRO FEATURE

Follow the institutions: 13F position changes, insider trades, and active 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Recent open-market insider transactions
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

This stock Peer Peer median weaker → stronger
P/Ebetter than 80% of peers
low 11.4x18.1xhigh 1236.3x
ROEbetter than 67% of peers
low -20%11%high 17%
Div yieldbetter than 50% of peers
low 0.0%1.7%high 3.0%

Algorithmic peers (6)

TickerCompanyMcapP/EROED/EYieldQuality
CIThe Cigna Group Common Stock$72.5B11.416.8%0.752.2%-Compare
CVSCVS Health Corporation Common Stock$112.0B23.16.2%0.863.0%-Compare
HUMHumana Inc. Common Stock$45.5B35.86.9%0.700.9%-Compare
CNCCentene Corporation Common Stock$32.1B--20.4%0.870.0%-Compare
UNHUnitedHealth Group Incorporated Common Stock (DE)$338.9B24.214.1%0.832.4%-Compare
MOHMolina Healthcare Inc Common Stock$10.3B1236.3-0.2%0.930.0%-Compare

Sector report card

Where ELV ranks against its sector peers on each metric.

Computing percentiles…

News and Record

Reports in 28 days, last quarter beat by 0.2%.

Press releases mentioning this company

Ask anything, Pro feature

Ask questions about this stock in plain language. Answered from company fundamentals + recent valuations.

PRO

Recent performance

1 week
-3.5%
1 month
+2.2%
3 months
+3.6%
6 months
+38.2%
YTD
+16.8%
1 year
+30.5%

SEC filings

40 filings
September 2026
Sep 10
8-KCurrent reportPeriod 2026-09-10
Sep 4
Form 4Insider transactionPeriod 2026-09-02
Sep 4
Form 4Insider transactionPeriod 2026-09-02
37 more filings + AI summaries on Investor+.INVESTOR